Welcome to our dedicated page for Acadia Pharmaceuticals SEC filings (Ticker: ACAD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acadia Pharmaceuticals' SEC filings reveal how this CNS-focused biopharmaceutical company balances commercial product revenue against substantial research and development investment. Understanding this dynamic requires examining both the profitability of approved therapies and the burn rate of clinical development programs.
The 10-K annual report details Acadia's product sales by indication, research and development expense breakdowns by clinical program, and the company's cash runway supporting ongoing operations. You'll find pipeline advancement timelines, patent expiration dates for approved products, and risk factors specific to CNS drug development including regulatory uncertainty and clinical trial failure rates. Our AI extracts these key metrics without requiring review of extensive accounting footnotes.
Acadia's 10-Q quarterly filings track prescription trends for commercial products, sequential changes in operating expenses, and clinical trial enrollment progress. Quarter-over-quarter comparisons reveal whether approved products are gaining market share and whether pipeline spending aligns with management's stated development timeline.
Form 4 insider transactions show when Acadia executives and directors purchase or sell company shares. Track executive stock activity around clinical trial readouts and FDA decision dates to understand insider sentiment before material announcements. Our platform aggregates these transactions across Acadia's leadership team.
8-K material event filings disclose clinical trial results, regulatory correspondence, significant contracts, and partnership announcements between quarterly reports. For a biotech company, 8-Ks often contain the most market-moving information including FDA approval letters and complete response notifications. DEF 14A proxy statements detail executive compensation tied to pipeline milestones and shareholder governance matters.
Access Acadia's complete SEC filing history with AI summaries that translate clinical and regulatory disclosures into actionable insights.
ACADIA PHARMACEUTICALS INC (ACAD) executive vice president and chief financial officer reported equity transactions in company stock. On 11/17/2025, restricted stock units converted into 9,913 shares of common stock twice, increasing directly held shares. On 11/18/2025, the reporting person sold 10,262 shares of common stock at a weighted average price of $23.6907 per share, with sales made in multiple trades between $23.69 and $23.77. After these transactions, the reporting person directly beneficially owned 53,338 shares of common stock. The filing notes that certain sales were mandatory to cover withholding taxes related to restricted stock unit vesting and are intended to meet Rule 10b5-1(c) requirements. The restricted stock units generally vest over four years, with 37.5% vesting 18 months from grant, 12.5% on the second anniversary, and 25% on each of the third and fourth anniversaries, and some awards may vest earlier if the stock reaches a specified price over a set trading period.
ACADIA Pharmaceuticals (ACAD) principal accounting officer reported equity transactions involving company stock. On 11/17/2025, 3,966 restricted stock units converted into 3,966 shares of common stock at an exercise price of $0, twice, increasing directly held shares. On 11/18/2025, 4,084 shares of common stock were sold at a weighted average price of $23.6909 to cover withholding taxes and related items in connection with restricted stock unit vesting, under a Rule 10b5-1(c) plan. Following these transactions, the reporting person directly owned 25,058 shares of ACADIA common stock. Some restricted stock units feature a multi-year vesting schedule and may vest earlier if the stock reaches specified price targets over a set trading period.
ACADIA Pharmaceuticals (ACAD) director reported an open-market sale of 30,000 shares of common stock on 11/10/2025 at a weighted average price of $22.3661. The filing notes the trades occurred across multiple transactions within a range of $22.14 to $22.63. After the sale, the reporting person beneficially owns 4,041 shares, held directly.
ACADIA Pharmaceuticals reported higher profitability with growing product sales. Total revenue reached $278,633 (in thousands) for the quarter, up from $250,401 (in thousands) a year ago, driven by NUPLAZID at $177,530 and DAYBUE at $101,103 (each in thousands). Net income rose to $71,779 (in thousands), and diluted EPS was $0.42, reflecting stronger operations and a tax benefit.
Operating expenses were $242,877 (in thousands) as R&D increased to $87,829 and SG&A was $133,401 (each in thousands). Cost of product sales was $21,647 (in thousands), about 8% of net product sales. The effective tax rate was -61.0%, influenced by the One Big Beautiful Bill Act (OBBBA) and an accounting method change, boosting quarterly after‑tax results.
The balance sheet remained solid: cash and cash equivalents were $257,996 and investment securities were $589,023 (each in thousands). Stockholders’ equity improved to $917,272 (in thousands) from $732,793 at year‑end, supported by nine‑month operating cash flow of $158,567 (in thousands). Shares outstanding were 169,181,817 as of October 29, 2025.
Acadia Pharmaceuticals Inc. furnished an 8-K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is provided as Exhibit 99.1.
The information in this report and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference except as specifically stated. The press release is dated November 5, 2025.
Acadia Pharmaceuticals Inc. announced that Daniel B. Soland has resigned from its Board of Directors and from his role as Chair of the Nominating and Corporate Governance Committee, effective October 30, 2025. The company stated that his resignation was not due to any dispute or disagreement regarding the company’s operations, policies, or practices.
Mark C. Schneyer, EVP & Chief Financial Officer of ACADIA Pharmaceuticals (ACAD), reported two transactions in September 2025. On 09/12/2025 he acquired 6,815 shares of common stock upon vesting of performance stock units granted May 1, 2023, representing an incremental 25% of target and bringing total PSU vesting to 75% of target. Following that acquisition his beneficial ownership rose to 46,945 shares.
On 09/15/2025 he sold 3,498 shares at $23.65 per share to satisfy withholding taxes and related tax items associated with the PSU vesting, leaving him with 43,447 shares beneficially owned. The sale was reported as a mandatory sale intended to comply with Rule 10b5-1(c) provisions.
Acadia Pharmaceuticals director Elizabeth A. Garofalo reported a sale of 1,600 shares of Acadia common stock on 09/02/2025 at a weighted average price of $25.9753. Following the sale, the reporting person beneficially owned 25,382 shares. The filer notes the reported price is a weighted average for multiple transactions that ranged from $25.97 to $25.991 and offers to provide details on quantities sold at each price upon request. The Form 4 was signed by an attorney-in-fact on 09/03/2025.
Mark C. Schneyer, EVP and Chief Financial Officer of Acadia Pharmaceuticals (ACAD), reported the sale of 22,000 shares of the issuer's common stock on 08/18/2025 at a weighted-average price of $25.1829 per share, with sale prices in the range $25.06 to $25.28. Following the reported disposition, Mr. Schneyer beneficially owned 40,130 shares. The Form 4 discloses the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2025. The filing was signed on behalf of the reporting person by an attorney-in-fact on 08/19/2025.
Acadia Pharmaceuticals (ACAD) filing a Form 144 to notify a proposed sale of securities. The notice identifies 22,000 shares of common stock to be sold through Piper Sandler & Co. on or about 08/18/2025, with an aggregate market value of $557,260.00. The filing shows the shares were acquired as compensation from the issuer on 11/17/2023 and payment was recorded on that date. The filing lists total shares outstanding as 168,712,220. Several standard filer and issuer identification fields in the form are blank, and no name is provided for the person on whose account the sale will occur.
FAQ
What is the current stock price of Acadia Pharmaceuticals (ACAD)?
What is the market cap of Acadia Pharmaceuticals (ACAD)?
